Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials
ABSTRACTVaccination plays a key role in preventing morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the safety and immunogenicity of a SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine SYS6006. In the two randomized, observer...
Spremljeno u:
Glavni autori: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Knjiga |
Izdano: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Teme: | |
Online pristup: | Connect to this object online. |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Primjerak 1 | Dostupno |